Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ReSearch Pharmaceutical Buys China CRO Paramax

publication date: Apr 6, 2009

ReSearch Pharmaceutical Services (RPS), a US-headquartered international CRO, will acquire Paramax International for $1 million and 530,973 shares of RPS common stock. Paramax is a CRO that is based in Beijing with offices in other China cities. RPS positioned the acquisition as an expansion of its global CRO business. The company bought three European CROs in late 2008, and it has operations in Central and South America as well. Paramax is the company’s first foray into Asia. More details..

Stock Symbol: (AIM: RPSE)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here